An epirubicin-peptide conjugate with anticancer activity is dependent upon the expression level of the surface transferrin receptor

Yang,Jiadan; Yang,Qiyu; Xu,Lu; Lou,Jie; Dong,Zhi

doi:10.3892/mmr.2016.6004

An epirubicin-peptide conjugate with anticancer activity is dependent upon the expression level of the surface transferrin receptor

Authors:
- Jiadan Yang
- Qiyu Yang
- Lu Xu
- Jie Lou
- Zhi Dong
View Affiliations

Affiliations: Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Thoracic Oncology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: December 7, 2016 https://doi.org/10.3892/mmr.2016.6004
Pages: 323-330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epirubicin (EPI) is one of the most widely used anticarcinogens; however, serious side effects, including cardiomyopathy and congestive heart failure, limit its long‑term administration. To overcome this problem, the HAIYPRH peptide ligand was used with EPI in the synthesis of a HAIYPRH‑EPI conjugate. The anticancer activity and cellular uptake of the conjugate were measured and evaluated. The results of the present study indicated that the cytotoxicity of HAIYPRH‑EPI was correlated with the expression of the cell surface transferrin receptor (TfR). The conjugate exerted high cytotoxicity and proapoptotic function when in an LN229 glioma cell line, which overexpresses surface TfR. It was hypothesized that transferrin (Tf) can promote cytotoxicity. Conversely, the conjugate exhibited very low cytotoxicity and proapoptotic function in a U87 glioma cell line, in which surface TfR expression was undetectable. In addition, fluorescence microscopy and flow cytometry methods were used to evaluate cellular uptake, and the results of these methods were consistent with the present hypotheses. The conjugate cellular uptake of the conjugate in LN229 cells was markedly higher compared with that in U87 cells, and it was hypothesized that Tf can enhance the uptake in LN229 cells. The cytotoxicity of HAIYPRH‑EPI was dependent upon the expression of surface TfR. Considering that the majority of cancer cells have high rates of iron uptake and surface TfR is generally overexpressed on cancer cells, it was speculated by the authors that HAIYPRH‑EPI may form part of an effective strategy for increasing the selectivity of EPI for cancer cells, as well as reducing its systemic toxicity. To confirm the hypothesis, the effects of HAIYPRH‑EPI on non‑cancerous cell lines were investigated. A future study will examine the side effects of HAIYPRH‑EPI, using a suitable delivery system in an animal model.

View Figures

View References

1	Hu DG, Rogers A and Mackenzie PI: Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway. Mol Pharmacol. 85:887–897. 2014. View Article : Google Scholar : PubMed/NCBI
2	Khasraw M, Bell R and Dang C: Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. Breast. 21:142–149. 2012. View Article : Google Scholar : PubMed/NCBI
3	Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kim SJ, Okishiro M, et al: Topoisomerase IIalpha-positive and BRCA1-negative phenotype: Association with favorable response to epirubicin-based regimens for human breast cancers. Cancer Lett. 264:44–53. 2008. View Article : Google Scholar : PubMed/NCBI
4	Okishiro M, Kim SJ, Tsunashima R, Nakayama T, Shimazu K, Shimomura A, Maruyama N, Tamaki Y and Noguchi S: MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. Breast Cancer Res Treat. 132:947–953. 2012. View Article : Google Scholar : PubMed/NCBI
5	Aogi K, Saeki T, Nakamura S, Kashiwaba M, Sato N, Masuda N, Rai Y, Ohno S, Kuroi K, Nishimura R, et al: A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). Int J Clin Oncol. 18:598–606. 2013. View Article : Google Scholar : PubMed/NCBI
6	Nasr M, Nafee N, Saad H and Kazem A: Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 88:216–225. 2014. View Article : Google Scholar : PubMed/NCBI
7	Appel JM, Zerahn B, Moller S, Christensen HM, Søgaard P, Ejlertsen B, Fogh-Andersen N, Jensen BV and Nielsen DL: Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer. Acta Oncol. 51:1054–1061. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng F, Zhou J, Liu L, Zhang CX, Zhao WY and Lu WL: Liposomes, modified with PTD (HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 35:7610–7621. 2014. View Article : Google Scholar : PubMed/NCBI
9	Haisma HJ, Boven E, van Muijen M, de Jong J, van der Vijgh WJ and Pinedo HM: A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer. 66:474–478. 1992. View Article : Google Scholar : PubMed/NCBI
10	Xu J, Sheng Y, Xu F, Yu Y and Chen Y: Quantitative subcellular study of transferrin receptor-targeted doxorubicin and its metabolite in human breast cancer cells. Eur J Drug Metab Pharmacokinet. 39:301–310. 2014. View Article : Google Scholar : PubMed/NCBI
11	Tortorella S and Karagiannis TC: Transferrin receptor-mediated endocytosis: A useful target for cancer therapy. J Membr Biol. 247:291–307. 2014. View Article : Google Scholar : PubMed/NCBI
12	Oh S, Kim BJ, Singh NP, Lai H and Sasaki T: Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett. 274:33–39. 2009. View Article : Google Scholar : PubMed/NCBI
13	Han L, Huang R, Liu S, Huang S and Jiang C: Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm. 7:2156–2165. 2010. View Article : Google Scholar : PubMed/NCBI
14	Malarvizhi GL, Retnakumari AP, Nair S and Koyakutty M: Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Nanomedicine. 10:1649–1659. 2014.PubMed/NCBI
15	Nam JP, Park SC, Kim TH, Jang JY, Choi C, Jang MK and Nah JW: Encapsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery. Int J Pharm. 457:124–135. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lee JH, Engler JA, Collawn JF and Moore BA: Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem. 268:2004–2012. 2001. View Article : Google Scholar : PubMed/NCBI
17	Kato J, Kobune M, Ohkubo S, Fujikawa K, Tanaka M, Takimoto R, Takada K, Takahari D, Kawano Y, Kohgo Y and Niitsu Y: Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation. Exp Hematol. 35:879–887. 2007. View Article : Google Scholar : PubMed/NCBI
18	Qian G, Wang Z, Zhao J, Li D, Gao W, Wang B, Sui D, Qu X and Chen Y: Synthesis and anti-cancer cell activity of pseudo-ginsenoside Rh2. Steroids. 92:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
19	Dixit S, Novak T, Miller K, Zhu Y, Kenney ME and Broome AM: Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale. 7:1782–1790. 2015. View Article : Google Scholar : PubMed/NCBI
20	Xu J, Sheng Y, Xu F, Yu Y and Chen Y: Quantitative subcellular study of transferrin receptor-targeted doxorubicin and its metabolite in human breast cancer cells. Eur J Drug Metab Pharmacokinet. 39:301–310. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wirth GJ, Schandelmaier K, Smith V, Burger AM and Fiebig HH: Microarrays of 41 human tumor cell lines for the characterization of new molecular targets: Expression patterns of cathepsin B and the transferrin receptor. Oncology. 71:86–94. 2006. View Article : Google Scholar : PubMed/NCBI
22	Lo YL, Ho CT and Tsai FL: Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur J Pharm Sci. 35:52–67. 2008. View Article : Google Scholar : PubMed/NCBI
23	Pakunlu RI, Wang Y, Saad M, Khandare JJ, Starovoytov V and Minko T: In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release. 114:153–162. 2006. View Article : Google Scholar : PubMed/NCBI
24	Lin Y, Jiang D, Li Y, Han X, Yu D, Park JH and Jin YH: Effect of sun ginseng potentiation on epirubicin and paclitaxel-induced apoptosis in human cervical cancer cells. J Ginseng Res. 39:22–28. 2015. View Article : Google Scholar : PubMed/NCBI
25	Richardson DR and Ponka P: The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta. 1331:1–40. 1997. View Article : Google Scholar : PubMed/NCBI
26	Yashunsky V, Shimron S, Lirtsman V, Weiss AM, Melamed-Book N, Golosovsky M, Davidov D and Aroeti B: Real-time monitoring of transferrin-induced endocytic vesicle formation by mid-infrared surface plasmon resonance. Biophys J. 97:1003–1012. 2009. View Article : Google Scholar : PubMed/NCBI